Drug Profile
Ilofotase alfa - AM-Pharma Holding
Alternative Names: Human recombinant alkaline phosphatase; recAP; Recombinant optimised human alkaline phosphataseLatest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator AM-Pharma Holding
- Developer AM-Pharma
- Class Anti-inflammatories; Anti-ischaemics; Recombinant proteins
- Mechanism of Action Endotoxin inhibitors; Enzyme replacements; Purinergic P1 receptor agonists; Purinergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Ulcerative colitis
Highest Development Phases
- Phase III Acute kidney injury
- Phase I/II Hypophosphatasia
- No development reported Ulcerative colitis
- Discontinued Septic shock
Most Recent Events
- 16 Jan 2024 Phase-II clinical trials in Acute kidney injury (Prevention) (IV) (NCT06168799)
- 13 Dec 2023 AM Pharma plans phase-II trial for Acute kidney injury (Prevention) in December 2023 (IV, infusion) (NCT06168799)
- 11 Oct 2023 Adverse events, pharmacokinetics and pharmacodynamics data from a phase-I/II trial in Hypophosphatasia released by AM Pharma